Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
Zacks News
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
by Zacks Equity Research
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 0% and 2.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PRFZ
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 4.35% and 3.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
by Zacks Equity Research
Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
by Zacks Equity Research
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.
Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
Here's Why You Should Retain Prestige Consumer (PBH) Stock Now
by Zacks Equity Research
The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
by Zacks Equity Research
ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today
by Zacks Equity Research
Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).
Myriad Genetics (MYGN) Announces Favorable Research Results
by Zacks Equity Research
Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
Zacks Investment Ideas feature highlights: Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies
by Zacks Equity Research
Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies are part of the Zacks Investment Ideas article.
Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $73.60 in the latest trading session, marking a -0.89% move from the prior day.
3 Buy-Rated Stocks Flexing Relative Strength
by Derek Lewis
While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three carrying a favorable Zacks Rank.